Rdl Financial Stake in Allstate (ALL) Has Decreased as Share Price Declined; Saba Capital Management LP Trimmed Its Position in Valeant Pharmaceuticals Intl (VRX) by $24.89 Million as Market Valuation Declined

April 18, 2018 - By Louis Casey

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) Logo

Boaz Weinstein decreased its stake in Valeant Pharmaceuticals Intl (VRX) by 92.23% based on its latest 2017Q4 regulatory filing with the SEC. Saba Capital Management Lp sold 1.24M shares as the company’s stock declined 28.77% with the market. The hedge fund run by Boaz Weinstein held 104,759 shares of the health care company at the end of 2017Q4, valued at $2.18 million, down from 1.35M at the end of the previous reported quarter. Saba Capital Management Lp who had been investing in Valeant Pharmaceuticals Intl for a number of months, seems to be less bullish one the $6.05B market cap company. The stock increased 0.64% or $0.11 during the last trading session, reaching $17.34. About 528,547 shares traded. Valeant Pharmaceuticals International, Inc. (NYSE:VRX) has risen 42.00% since April 18, 2017 and is uptrending. It has outperformed by 30.45% the S&P500.

Rdl Financial Inc decreased its stake in Allstate Corp (ALL) by 12.66% based on its latest 2017Q4 regulatory filing with the SEC. Rdl Financial Inc sold 3,475 shares as the company’s stock declined 10.30% with the market. The institutional investor held 23,964 shares of the property-casualty insurers company at the end of 2017Q4, valued at $2.51 million, down from 27,439 at the end of the previous reported quarter. Rdl Financial Inc who had been investing in Allstate Corp for a number of months, seems to be less bullish one the $34.49 billion market cap company. The stock decreased 0.08% or $0.08 during the last trading session, reaching $97.67. About 81,673 shares traded. The Allstate Corporation (NYSE:ALL) has risen 15.17% since April 18, 2017 and is uptrending. It has outperformed by 3.62% the S&P500.

Among 22 analysts covering The Allstate Corporation (NYSE:ALL), 8 have Buy rating, 1 Sell and 13 Hold. Therefore 36% are positive. The Allstate Corporation had 56 analyst reports since August 4, 2015 according to SRatingsIntel. Keefe Bruyette & Woods maintained the shares of ALL in report on Friday, October 6 with “Hold” rating. The rating was maintained by FBR Capital with “Mkt Perform” on Monday, April 3. The stock of The Allstate Corporation (NYSE:ALL) has “Equal-Weight” rating given on Wednesday, February 21 by Morgan Stanley. Deutsche Bank upgraded The Allstate Corporation (NYSE:ALL) on Monday, August 10 to “Hold” rating. The firm has “Outperform” rating by Macquarie Research given on Tuesday, January 19. Buckingham Research initiated the shares of ALL in report on Monday, September 11 with “Sell” rating. Goldman Sachs downgraded The Allstate Corporation (NYSE:ALL) on Tuesday, August 4 to “Neutral” rating. Goldman Sachs upgraded The Allstate Corporation (NYSE:ALL) on Tuesday, January 10 to “Buy” rating. The firm has “Buy” rating given on Thursday, February 8 by Bank of America. The stock has “Neutral” rating by UBS on Monday, November 6.

Analysts await The Allstate Corporation (NYSE:ALL) to report earnings on May, 1 after the close. They expect $2.40 EPS, up 46.34% or $0.76 from last year’s $1.64 per share. ALL’s profit will be $847.53M for 10.17 P/E if the $2.40 EPS becomes a reality. After $2.09 actual EPS reported by The Allstate Corporation for the previous quarter, Wall Street now forecasts 14.83% EPS growth.

Investors sentiment increased to 0.96 in Q4 2017. Its up 0.05, from 0.91 in 2017Q3. It increased, as 43 investors sold ALL shares while 308 reduced holdings. 101 funds opened positions while 236 raised stakes. 266.22 million shares or 1.14% more from 263.23 million shares in 2017Q3 were reported. Blb&B Advsrs Ltd Liability Company accumulated 9,009 shares. Camarda Limited Co reported 5,218 shares or 0.65% of all its holdings. Dean Invest Assoc reported 8,627 shares. Texas Permanent School Fund holds 97,956 shares or 0.13% of its portfolio. Omers Administration invested in 0.07% or 65,300 shares. Wealthtrust stated it has 0.06% in The Allstate Corporation (NYSE:ALL). Segment Wealth Mgmt Ltd Limited Liability Company invested in 0.86% or 33,884 shares. Liberty Mutual Grp Inc Asset Management Inc reported 14,402 shares. 660,079 were accumulated by State Teachers Retirement Systems. First Business Svcs owns 8,579 shares for 0.16% of their portfolio. 507,610 were accumulated by Barclays Public Ltd Com. Koch Inc holds 0.12% of its portfolio in The Allstate Corporation (NYSE:ALL) for 7,568 shares. And Mngmt holds 985 shares. Sawgrass Asset Mngmt Limited Liability stated it has 0.03% of its portfolio in The Allstate Corporation (NYSE:ALL). Parametric Port Limited, Washington-based fund reported 1.53M shares.

Among 28 analysts covering Valeant Pharmaceuticals Intl (NYSE:VRX), 7 have Buy rating, 5 Sell and 16 Hold. Therefore 25% are positive. Valeant Pharmaceuticals Intl had 162 analyst reports since July 21, 2015 according to SRatingsIntel. The stock of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) has “Underweight” rating given on Thursday, December 14 by JP Morgan. The rating was maintained by RBC Capital Markets with “Outperform” on Tuesday, October 27. The firm has “Buy” rating by Cantor Fitzgerald given on Tuesday, August 29. The stock of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) has “Buy” rating given on Wednesday, March 16 by Rodman & Renshaw. The stock has “Hold” rating by Canaccord Genuity on Tuesday, October 3. On Thursday, December 14 the stock rating was downgraded by J.P. Morgan to “Sell”. Cantor Fitzgerald initiated Valeant Pharmaceuticals International, Inc. (NYSE:VRX) rating on Friday, June 16. Cantor Fitzgerald has “Overweight” rating and $18 target. The stock of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) earned “Buy” rating by Jefferies on Friday, June 9. The stock has “Buy” rating by BTIG Research on Tuesday, July 21. The stock of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) earned “Sell” rating by Wells Fargo on Monday, July 17.

Since March 8, 2018, it had 3 insider buys, and 0 selling transactions for $876,370 activity. 15,000 shares were bought by Herendeen Paul, worth $241,470. Shares for $153,400 were bought by DE SCHUTTER RICHARD U.

Investors sentiment decreased to 0.97 in 2017 Q4. Its down 0.02, from 0.99 in 2017Q3. It is negative, as 51 investors sold VRX shares while 74 reduced holdings. 54 funds opened positions while 67 raised stakes. 169.66 million shares or 0.12% less from 169.87 million shares in 2017Q3 were reported. Hightower Advsr Ltd Llc owns 233,012 shares or 0.04% of their US portfolio. Boothbay Fund Ltd Llc stated it has 0.15% in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). Sg Americas Secs Limited invested in 0.28% or 1.44M shares. Advisory Svcs Networks Ltd Liability Company holds 0.02% or 10,768 shares in its portfolio. Barnett And has invested 0% in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). 686,078 were accumulated by Bogle Management LP De. Gargoyle Advisor Limited Liability Company accumulated 18,858 shares. Live Your Vision Limited Liability Company invested in 0% or 32 shares. Bnp Paribas Arbitrage has 70,687 shares. Acadian Asset Mngmt Ltd Co reported 368,617 shares. Royal National Bank Of Canada holds 0.03% or 2.93 million shares. Dimensional Fund Advsrs LP holds 5.19M shares. Hillsdale Investment Mngmt, Ontario – Canada-based fund reported 344,300 shares. Her Majesty The Queen In Right Of The Province Of Alberta As Represented By Alberta Inv Management Corp stated it has 0.01% of its portfolio in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). Greenleaf Trust has 0.01% invested in Valeant Pharmaceuticals International, Inc. (NYSE:VRX).

Analysts await Valeant Pharmaceuticals International, Inc. (NYSE:VRX) to report earnings on May, 8 before the open. They expect $0.66 earnings per share, down 76.43% or $2.14 from last year’s $2.8 per share. VRX’s profit will be $230.24M for 6.57 P/E if the $0.66 EPS becomes a reality. After $0.98 actual earnings per share reported by Valeant Pharmaceuticals International, Inc. for the previous quarter, Wall Street now forecasts -32.65% negative EPS growth.

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: